Clinical Trial Update: Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment [Phase 2]

View source ↗

Summary

A Phase 2 two-part study evaluating dose determination and subsequent expansion for vesleteplirsen (SRP-5051) in Duchenne muscular dystrophy amenable to exon 51…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Vesleteplirsen (SRP-5051) (vesleteplirsen)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: TERMINATED